Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 11/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 11/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 10/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 9/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.55 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26330969 | 0.83 | CACNA2D1 (0.81) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| Hydrochloric Acid SCHEMBL4588106 | 0.81 | GPR119 (0.51) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7411201 | 0.81 | MC4R (0.51) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7411206 | 0.81 | MC4R (0.51) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL4013471 | 0.80 | KMT2A (0.67) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL4720508 | 0.80 | HSD11B1 (0.60) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8268615 | 0.79 | CACNA2D1 (0.71) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL2954681 | 0.79 | TSHR (0.51) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3805489 | 0.79 | CYP2D6 (0.57) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8115616 | 0.79 | CYP2D6 (0.57) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231350-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231350-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130184290-A1 | SELF-EMULSIFYING FORMULATIONS AND METHODS OF USE THEREOF | CAPSUGEL, Inc. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184290-A1 | SELF-EMULSIFYING FORMULATIONS AND METHODS OF USE THEREOF | CAPSUGEL, Inc. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8409560-B2 | Solid dispersion formulations and methods of use thereof | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-8409560-B2 | Solid dispersion formulations and methods of use thereof | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20130035345-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-02-07 | — | — | US | disclosed |
| US-20130035345-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-02-07 | — | — | US | disclosed |
| US-20120252819-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. | 2012-10-04 | — | — | US | disclosed |
| US-20120252819-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. | 2012-10-04 | — | — | US | disclosed |
| WO-2007118323-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118323-A1 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-10-25 | — | — | WO | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| EP-1670775-A1 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005021523-A1 | PIPERAZINE SUBSTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-10 | — | — | WO | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231350-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | SLC6A7, SLC6A1, PRNP | CACNA2D1 3684/4885CACNB1 1597/4885CACNA1B 1368/4885 |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CACNA2D1 36/4885CACNB1 13/4885CACNA1B 1/4885 |
| US-20130184290-A1 | SELF-EMULSIFYING FORMULATIONS AND METHODS OF USE THEREOF | NPC1L1, LIPA, NPC1 | CACNA2D1 3981/4885CACNB1 2001/4885CACNA1B 2241/4885 |
| US-20130035345-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | SLC6A7, SLC6A1, PRNP | CACNA2D1 3684/4885CACNB1 1597/4885CACNA1B 1368/4885 |
| US-20120252819-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | SLC6A7, SLC6A1, PRNP | CACNA2D1 3684/4885CACNB1 1597/4885CACNA1B 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.